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Abstract
In current protocols for treatment of acute lym-
phoblastic leukemia in childhood methotrexate
(MTX) is one of the crucial cytostatics. The occur-
rence of MTX toxicity is still а great problem be-
cause of the interpatient differences in drug me-
tabolism. These differences may be due to poly-
morphisms of genes involved in the folate meta-
bolism.  The present study was carried out to de-
termine the prevalence of MTHFR C677T poly-
morphism in children with acute lymphoblastic
leukemia (ALL). Also the effect of the genotype on
the toxic effects during therapy with high doses
of МТХ in 45 patients with ALL treated in accor-
dance with the protocol ALL BFM 95 and ALL
BFM 2000 was evaluated. All 45 patients with ALL
were genotyped for MTHFR C677T polymorphism.
Correlation with the presence of a certain poly-
morphism and toxic effects of the chemotherapy
with high doses of МТХ was made in the Depar-
tment for hematology and oncology at the Uni-
versity Clinic for children’s diseases – Skopje. The
control group included 32 healthy patients. In the
study group 24 (53.3%) children had a wild type of
polymorphism (CC),  15 (33.33%) children were he-
terozygous (CT) for MTHFR C677T polymorphism,
and 6 (13.33%) children were homozygous for the
variant type of the polymorphism (ТТ). The cor-
relation of the genotype with МТХ toxicity indi-
cated a statistical significance only for oral mu-
cositis, while for the other toxic effects there was
no statistically significant correlation. In our stu-
dy the results indicated that oral mucositis was
statistically significantly more frequently identi-
fied in the case of the variant carriers for this po-
lymorphism. For the other toxic effects caused by
the therapy with high doses of МТХ no statisti-
cally significant correlation with MTHFR C677T
polymorphism was identified. This occurrence
maybe due to the small number of patients ana-
lyzed in this study and the possible protective in-
fluence of other genetic polymorphisms included
in the folate metabolism, which were not subject
to consideration of this study. 
Key words: acute lymphoblastic leukemia, met-
hotrexate, toxic effects, MTHFR, polymorphisms
Извадок
Во актуелните протоколи за третман на акутна
лимфобластна леукемија во детската возраст
метотрексатот (МТХ) е еден од круцијалните ци-
ВЛИЈАНИЕТО НА Ц677Т ПОЛИМОРФИЗМОТ НА
ГЕНОТ ЗА МТХФР ВРЗ ИНЦИДЕНЦИЈАТА НА
ТОКСИЧНИТЕ ЕФЕКТИ ОД ВИСОКИТЕ ДОЗИ МТХ КАЈ
ДЕЦА СО АКУТНА ЛИМФОБЛАСТНА ЛЕУКЕМИЈА
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тостатици. Предвидувањето на појавата на ток-
сични ефекти во тек на терапијата со МТХ пре-
тставува сè уште голем проблем заради индиви-
дуалните разлики во метаболизмот на лекови кај
пациентите. Овие разлики можеби се должат на
присуство на полиморфизми на гените вклуче-
ни во фолатниот метаболизам. Целта на сту-
дијата беше да се одреди инциденцијата на
МТХФР Ц677Т полиморфизмот кај децата со
акутна лимфобластна леукемија (АЛЛ) и да се
анализира влијанието на генотипот врз мани-
фестацијата на токсичните ефекти во тек на те-
рапија со високи дози МТХ кај пациенти со АЛЛ
третирани по протоколот АЛЛ БФМ 95. Беше
вклучена и контролна група од 32 здрави испи-
таници. Беше направена генотипизација за по-
лиморфизмот Ц677Т кај 45 пациенти со АЛЛ и
негова корелација со токсичните ефекти од хе-
мотерапијата со високи дози МТХ анализирани
од болничките истории на пациенти со АЛЛ ле-
кувани на Одделот за хематологија и онкологија
при ЈЗУ Универзитетска клиника за детски бо-
лести - Скопје. Во студиската група 15 (33,33%) па-
циенти беа хетерозиготи (ЦТ) за полиморфизмот
Ц677Т на генот MTHFR, а 6 (13,33%) пациенти хо-
мозиготи (ТТ). Во контролната група 10 испита-
ници (31,25%) беа хетерозиготи за полиморфиз-
мот (ЦТ), а 6 испитаници (18,75%) хомозиготи (ТТ).
Корелацијата на генотипот со токсичните ефек-
ти од високите дози на МТХ покажа статистич-
ка сигнификантност само за орален мукозит, до-
дека беше статистички несигнификантна за ос-
танатите токсични ефекти. Оваа појава можеби
се должи на малата група пациенти којашто бе-
ше анализирана во оваа студија и можното про-
тективно влијание на други генски полимор-
физми вклучени во фолатниот метаболизам, а
кои не беа предмет на оваа студија. 
Клучни зборови: акутна лимфобластна леуке-
мија, метотрексат, токсични ефекти, МТХФР, по-
лиморфизми
Introduction
The acute lymphoblastic leukemia (ALL) is the
most common type of cancer in childhood and it
accounts for almost one third of all malignant di-
seases in children. The optimization of the che-
motherapy regimens in the treatment of ALL led
to complete remission in 95% of patients during
treatment, and in 80% thereof a total success of
the treatment is noted. Once the main study gro-
ups reached comparable results in the treatment
of childhood ALL with current protocols, the fo-
cus of their attention is the reduction of acute
and late toxic effects of chemotherapy, as well as
the improvement of the outcome in case of pati-
ents with poor prognosis1. Predicting the toxic ef-
fects of chemotherapy is difficult taking into con-
sideration the large differences between patients
in terms of pharmacokinetics and pharmacody-
namics of anti-leukemic agents. This diversity
can, to some extent, be linked to sequence varia-
tions in genes involved in drug absorption, excre-
tion, cellular transport and effector targets or tar-
get pathways.2 Pharmacogenetics, the study of ge-
netic variations in drug processing genes, may be
used as a tool to further improve the treatment
of childhood ALL as well to predict toxic effects of
chemotherapy.
In all protocols for treatment of ALL, methotre-
xate (MTX) is one of the crucial cytostatics. It in-
hibits the function of the enzyme dihydrofolate
reductase (DHFR), inhibiting the folate metabo-
lism and indirectly interrupting the function of
the enzyme methylenetetrahydrofolate reducta-
se (MTHFR). MTHFR enzyme catalyzes the reduc-
tion of 5,10-methylenetetrahydrofolate required
for purine and thymidine synthesis to 5- methy-
lenetetrahydrofolate which is required for prote-
in synthesis and nucleic acid methylation. Alte-
rations in reduced folate pools, as a consequence
of changes in MTHFR activity, may have a signifi-
cant effect on the responsiveness of malignant
and non-malignant cells to MTX. It has been pro-
posed that alterations in intracellular folate pool
could increase the toxic effects of MTX 3.
One of the most common polymorphisms of the
MTHFR gene is the C677T polymorphism. MTHFR
C677T polymorphism is characterized by replace-
ment of the amino acid alanine with valine lea-
ding to reduced activity and thermolability of the
enzyme3. The activity of MTHFR enzyme in the va-
riant carriers of this polymorphism (TT) is 30%,
and in heterozygous cases (CT) is 60% of the nor-
mal activity of the enzyme 4,5.
The frequency of MTHFR C677TT genotype is of-
ten reported to be high in European, Asian Cen-
tral and South American (10-32%) populations,
low in different African populations (0-3%) and al-
so showing geographical gradients among Chine-
se Han populations 4. 
Several studies in ALL have suggested that varia-
tions in single nucleotide polymorphisms of genes
involved in folate metabolism contribute to the in-
ter-individual variation in MTX toxicity 6,7. The re-
sults are still controversial. 
The aim of this study was to identify the distribu-
tion of MTHFR C677T polymorphism in children
with ALL and to analyze the influence of this po-
lymorphism over the manifestation of toxic ef-
fects during therapy with high doses of МТХ in pa-
tients with ALL treated according to ALL BFM 95
and ALL BFM 2000 protocols.
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Material and methods
This was a retrospective study comprising 45
children (stratified in standard and medium
risk groups) treated with high doses of
MTX(5g/m2) for ALL at the University Children’s
Hospital, Department of Hematology and On-
cology in Skopje as a study group and 32 heal-
thy volunteers as a control group. The study was
approved by the National Ethics Committee of
the Republic of Macedonia and informed con-
sent was obtained by parents and patients be-
fore inclusion in the study.
Toxicity assessment
The data were collected from medical records of
patients with ALL treated according to ALL BFM
95 and ALL BFM 2000 protocols. To evaluate the
occurrence of toxic effects during therapy with
high doses of МТХ a total number of 180 cycles
of high doses MTX were analyzed. Every patient
has received four cycles of high doses MTX, each
separated by a period of two weeks. The toxic ef-
fects were analyzed according to the toxicity cri-
teria from the protocol ALL BFM 95 and ALL
BFM 2000. We collected the following data for
each course of the treatment: presence of mu-
cositis (oral and intestinal), hemoglobin level,
leukocyte and thrombocyte count, presence of
neurotoxicity signs (peripheral and central), skin
changes and level of liver enzymes.  Subsequen-
tly, the toxic effects were analyzed in correlati-
on to the genotype. 
Isolation of DNA
From each patient 3 ml peripheral blood with ED-
TA as anti-coagulant were taken. Subsequently, a
standard salting – out protocol with 5М NaCl was
used to isolate genomic DNA from peripheral leu-
kocytes obtained from venous blood draws. 
Genotyping of the C677T polymorphism 
in the MTHFR gene
Genotyping was conducted in line with the follo-
wing procedure:
The region of the MTHFR gene was amplified by
polymerase chain reaction using appropriate oli-
gonucleotide primer pair (according to Bagheri et
al., 2010, ordered from Sigma-Genosys); thermos-
table Taq polymerase, PCR buffer factory prepa-
red with magnesium ions, a mixture of deoxy-
nucleotides (dNTP) and a sample of DNA from a
subject in reactive test tubes with thin walls. Am-
plification program is used in PCR-machine (Per-
kin-Elmer GeneAmp System 2400). The success of
the amplification was verified by horizontal aga-
rose electrophoresis and fluorescence staining of
the gel with ethidium bromide. The gel is photog-
raphed under UV - light (312 nm) with a digital ca-
mera (Canon).
The digital analysis (identification of electrop-
horetic bands and determining their length in
base pairs) was carried out by option for analysis
of one-dimensional gels software Image J of NIH.
The amplification product has a length of 265
base pairs (bp). Amplified products were digested
with restriction endonuclease Hinfl under opti-
mal conditions in order to determine the geno-
type of the C677T polymorphism (wild type – CC,
heterozygous - CT and variant type – TT).
For the purposes of the statistical data analysis,
the software SPSS for Windows 13,0 was used. Fis-
her’s exact test was used for testing the signifi-
cance of the differences.
Results
After performed genotyping in both groups and
after analysis of the toxicity occurrence in 45
patients with ALL and correlation thereof with
the genotype, the following results have been
obtained. 
The prevalence of the polymorphism in the study
and control group is provided in Table 1.
The results from the analyzed distribution of
MTHFR C677T polymorphism in the study group
indicated that 24 (53.33%) patients were carriers
of the wild genotype (CC), 15 (33.33%) were hetero-
zygous (CT), and the remaining 6 (13.33%) were ho-
mozygous for the variant type of the polymor-
phism (ТТ).
In the control group of 32 healthy analyzed sub-
jects, the following results have been obtained: 16
persons (50%) were carriers of the wild genotype
(CC), 10 persons (31.25%) were heterozygous for the
polymorphism (CT), and 6 persons (18.75%) were
homozygous for the variant type (ТТ).
Toxic effects were analyzed in all four phases of
the M protocol in correlation to the genetic profi-
le of the patients who had shown toxic effects. The
results obtained are presented in Tables 2, 3, 4, 5.
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Table 1: 
Prevalence of 
the MTHFR C677T 
polymorphism
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The results of the analysis indicated that the oral
mucositis was more often in carriers of the vari-
ant type for this polymorphism, but it was statis-
tically significant more often only after the appli-
cation of the second dose of МТХ (p=0.018).
As regards to the correlation of the other toxic
effects in correlation to the genotype, no statis-
tical significance was identified among the three
groups.
DISCUSSION
High doses of МТХ are effective in the treatment
of many malignant diseases, especially leuke-
mias and lymphomas. MTX after polyglutamati-
on in the cell by the enzyme folylpolyglutamate
synthetase in the form of MTX polyglutamate
blocks the DHFR enzyme, which catalyzes the
conversion of folate into its active form tetra-
hydrofolate. In addition, МТХ polyglutamates in-
hibits the activity of other enzymes involved in
folate metabolism including MTHFR. The inci-
dence of toxic effects during treatment with
МТХ is characterized by interindividual and in-
terethnic variations and may influence the cli-
nical course of the disease8. Due to the establis-
hed prognostic factors in children with ALL, the
number of relapses and fatal outcomes in these
patients is limited. The gene polymorphisms in-
volved in the metabolism of МТХ are reported
as one of the possible predictive factors for the
Table 3: 
Toxic effects in 
correlation with 
genotype 
(after second 
dose MTX)
p (Fisher exact test for 3 x 2 groups)
Table 4: 
Toxic effects in 
correlation with 
genotype 
(after third 
dose MTX)
p (Fisher exact test for 3 x 2 groups)
Table 5: 
Toxic effects 
in correlation 
with genotype 
(after fourth 
dose MTX)
p (Fisher exact test for 3 x 2 groups)
Table 2:
Toxic effects in 
correlation with 
genotype 
(after first dose MTX)
p (Fisher exact test for 3 x 2 groups)
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manifestation of toxic effects due to the appli-
cation of this agent.
C677T polymorphism is one of the most investi-
gated polymorphisms of genes involved in folate
metabolism. Its association with cardiovascular
diseases, dementia, neural tube defects, autism,
recurrent spontaneous abortion, etc, has been
subject to research. In many studies related to the
pediatric oncology, its association with the oc-
currence of ALL, with the manifestation of the to-
xic effects of high doses of MTX, with the risk of
relapse as predictive for outcome of therapy, has
been studed. 
In the meta-analysis of Lin Yang it is reported
that MTHFR C677T polymorphism is associated
with a significantly increased risk of manifesta-
tion of toxicity during therapy with high doses
of MTX, especially hepatotoxicity, myelosuppre-
ssion, oral mucositis, gastrointestinal toxicity
and skin toxicity. During stratification of pati-
ents according to their ethnicity they identified
that among African and White population the
association between this polymorphism and he-
patotoxicity was more common, while it was not
present in the Asian population. On the other
side, oral mucositis was more common in pati-
ents - carriers of this polymorphism in African
and Asian populations9. In a meta-analysis of ni-
ne studies conducted by Lopez-Lopez E. an as-
sociation of this polymorphism with the toxic ef-
fects of high doses of MTX was identified. In
three of them the association of this polymor-
phism with hepatotoxicity, renal toxicity and in-
testinal mucositis was determined, while in two
studies the association of this polymorphism
with thrombocytopenia, neutropenia and oral
mucositis was reported4.
On the other side, the studies of Shimasaki and
Seidemann failed to confirm the association bet-
ween MTHFR C677T polymorphism and the to-
xic effects of high doses of МТХ 10,11.
In our study the results showed that oral muco-
sitis was more common in carriers of the vari-
ant type (MTHFR 677TT) of this polymorphism,
but this was statistically significant only after
the application of the second dose of MTX (p =
0.018). This results are in agreement with the re-
sults of the Faganel’s study, which showed sig-
nificant association between the MTHFR C677T
polymorphism and mucositis 12. For the other to-
xic effects caused by the treatment with high do-
ses of MTX no statistically significant correlati-
on with genotype was identified. This pheno-
menon might be due to the small group of pati-
ents that were analyzed in this study and the
possible protective influence of other gene po-
lymorphisms involved in folate metabolism,
which were not the subject of this study.
Regarding the prevalence of the C677T poly-
morphism our results were similar to the pre-
valence of this polymorphism reported for the
European population in the literature 4, both in
the group of patients with ALL and the control
group.
Several authors discussed that the discrepancy
between studies regarding the influence of po-
lymorphisms on the incidence of toxic effects
might be due to the influence of external fac-
tors, nutrition (folate status) of the patients and
the concurrent medications12,13. In addition, the
importance of the interaction between many ge-
nes involved in folate metabolism and their im-
pact on the modification of the sensitivity of
high doses of MTX is being emphasized. A num-
ber of studies have been dedicated to the study
of gene-gene interaction, including two or more
genes in association with the toxic effects of
MTX, the risk of relapse and event-free survival
in patients with ALL.
It is considered that the genotyping of polymor-
phisms involved in folate metabolism is neces-
sary in order to optimize MTX therapy resulting
in minimization of the toxic effects of treat-
ment. This will lead towards improvement of
the tolerance of the agent and achieving better
results in terms of survival9.
Conclusions
Nowadays almost 90% of children with ALL can
be cured with the existing therapy protocols.
However, better treatment for all children, 10%
of patients who cannot be cured and 90% of tho-
se treated with cytotoxic drugs is still subject to
research. The genotyping of polymorphisms in-
volved in folate metabolism is considered to be
necessary in the future before initiating thera-
py in any patient with ALL. It will open possibi-
lity of individual drug dose adjustment: patients
who have lower chemotherapy toxicity and lo-
wer event free survival might benefit from in-
crease of the drug dosage. But, it seems that ge-
notyping of only one polymorphism is not suffi-
cient; more and more emphasis is dedicated to
the importance of the interaction between ge-
nes involved in folate metabolism and their im-
pact on the modification of the sensitivity of
high doses of MTX.
Genetics has played an important role in the last
25 years in the treatment of ALL and it is pro-
mising an opportunity for a radical change in the
treatment of ALL in the next decade by providing
diagnostics that will lead to individualization of
therapy - an opportunity for each patient to ha-
ve an individual dosage and pattern of specific
Vol.7  No.1  2015
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combination of chemoterapeutics. Each patient
will receive the necessary treatment in accor-
dance to his/her own genotype, with minimal
risk of adverse toxic effects, failure of therapy,
risk of relapse of the disease and an opportuni-
ty for good quality of life in the future.
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